Nitto Denko Acquires Avecia Biotechnology

The deal follows Nitto Denko's establishment of an siRNA drug-development deal with Quark Pharmaceuticals.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.